Abstract
Hairy cell leukemia (HCL) is a distinct
subset of chronic lymphoid leukemia, presents with unique features, including
the characteristic "hairy" projections seen in neoplastic B cells. We
reported a case on hairy cell leukemia (HCL), emphasizing the challenges posed
by this rare hematological malignancy, especially in the context of concurrent
health crises such as the COVID-19 pandemic. This malignancy, though uncommon,
necessitates comprehensive diagnostic methodologies, such as peripheral blood
studies, flow cytometry, and bone marrow biopsy.
Treatment strategies for HCL involve
tailored approaches based on symptomatic presentations. Purine analogs,
cladribine and pentostatin, stand as first-line interventions, showcasing
efficacy in inducing and sustaining remission. However, the prolonged immunosuppression
resulting from these treatments warrants vigilant monitoring for potential
infectious complications. Emerging therapies, such as the BRAF inhibitor
vemurafenib, provide additional options for refractory or progressive cases.
The post-treatment phase demands meticulous
follow-up, with an emphasis on regular blood work assessments by an oncology
nurse and primary care physician.
Our case further highlights the need for
heightened awareness among healthcare professionals, particularly in the
post-COVID-19 phase, where persistent symptoms led to the discovery of an
underlying hematological disorder.
Keywords: Hairy cell leukemia, Evan syndrome, Covid-19.